Menu
Search
|

Menu

Close
X

Agios Pharmaceuticals Inc AGIO.OQ (NASDAQ Stock Exchange Global Select Market)

48.58 USD
+0.08 (+0.16%)
As of 1:13 PM EDT
Previous Close 48.50
Open 48.56
Volume 62,672
3m Avg Volume 176,633
Today’s High 48.91
Today’s Low 48.37
52 Week High 94.38
52 Week Low 41.63
Shares Outstanding (mil) 58.71
Market Capitalization (mil) 2,847.50
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 12 analysts

KEY STATS

Revenue (mm, USD)
FY19
30
FY18
94
FY17
43
FY16
70
EPS (USD)
FY19
-1.592
FY18
-6.030
FY17
-6.743
FY16
-5.058
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.10
Price to Sales (TTM)
vs sector
24.58
7.99
Price to Book (MRQ)
vs sector
4.59
4.39
Price to Cash Flow (TTM)
vs sector
--
24.00
Total Debt to Equity (MRQ)
vs sector
0.00
17.94
LT Debt to Equity (MRQ)
vs sector
0.00
12.82
Return on Investment (TTM)
vs sector
-40.81
12.64
Return on Equity (TTM)
vs sector
-46.88
17.18

EXECUTIVE LEADERSHIP

David Schenkein
Executive Chairman of the Board, Since 2019
Salary: $625,000.00
Bonus: --
Jacqualyn Fouse
Chief Executive Officer, Director, Since 2019
Salary: --
Bonus: --
Andrew Hirsch
Chief Financial Officer, Since 2016
Salary: $471,329.00
Bonus: --
Orlando Oliveira
Senior Vice President, General Manager, International, Since 2019
Salary: --
Bonus: --
Darrin Miles
Senior Vice President, U.S. Commercial and Global Marketing, Since 2019
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

88 Sidney St
CAMBRIDGE   MA   02139-4137

Phone: +1617.6498600

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.

SPONSORED STORIES